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ABSTRACT
Background: Previous studies show that depression plays an important role in asthma. However, the asso-
ciation between asthma control and severity, and depression is inconclusive.
Methods: To investigate the association between asthma control and severity, and depression, we assessed
differences in asthma control and asthma severity between groups with various grades of depressive state as
defined by the PHQ-9 score using data from the Japanese version of Patient Health Questionnaire-9 (J-PHQ-9)
and a questionnaire survey including the Asthma Control Test (ACT).
Results: The ACT scores in the symptom-screen positive (SP) and majorother depressive disorder (MDD
ODD) group were significantly lower than those in the symptom-screen negative (SN) and non-MDDODD
groups, respectively. The rate of step1 and of step 3 and 4 in the SP group were significantly lower and higher
than those in the SN group, respectively. When the SP group was divided into three, that is minimal, mild, and
more than mild (MTM) depressive state subgroups, the ACT scores in the mild and MTM depressive state sub-
groups were significantly lower than those in the minimal depressive state subgroup. When the MTM subgroup
was divided into moderate, moderate-severe and severe depressive state groups, however, there was no sig-
nificant variation in ACT score and asthma severity among these three depressive state groups.
Conclusions: This study is the first, large-scale investigation of the use of the J-PHQ-9 in asthma patients.
Using the J-PHQ-9 and the questionnaire, there was a clear association between asthma control and severity,
and depression. As the depression became more severe, the existence of other depression-associated factors
unrelated to asthma control and severity might be assumed, although further investigation will be required.
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Questionnaire-9; MTM subgroup, moderate, moderate-severe and severe groups.
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INTRODUCTION
The association between asthma and psychological
factors has been recognized for centuries.1 After vary-
ing degrees of confusion about the relationship be-
tween these two conditions, it is currently thought
that the condition of asthma is not due to but is af-
fected by psychological factors.2 Among the various
factors, depression plays a key role in the manage-
ment of asthma, because health-related quality of life,
one of the most important goals of asthma manage-
ment, is reduced by the onset of depression.3,4 In sec-
ondary care populations up to 50% of patients with
asthma have been reported to have clinically signifi-
cant depressive symptoms and over a third of asth-
matic outpatients have been found to have a major de-
pressive episode.5-10 Large-scale studies found an
age- and sex-adjusted odds ratio of 1.6 for depression
in people with asthma compared to people without
asthma.11-13
While it seems logical that having more severe
asthma and asthma that is difficult to treat would be
associated with an increased risk of depression, stud-
ies have reported somewhat mixed results. In investi-
gations that used objective measures of asthma sever-
ity (i.e. clinician diagnoses, airway reactivity testing),
some studies report that more severe asthma was as-
sociated with increased depressive symptoms.14 Like-
wise, two studies that used patients’ subjective rat-
ings of their own asthma severity found significant re-
lationships between perceived asthma severity and
depressive symptoms.15,16 However, this association
was not found in other studies,17,18 indicating that the
evidence so far does not strongly support a direct re-
lationship between objective asthma severity and de-
pression. Thus, there is some controversy about the
relationship between the severitycontrol of asthma
and depression.
The Niigata Asthma Treatment Study Group has
been carrying out a regular questionnaire on prob-
lems related to asthma management since 1998. The
subjects surveyed are adult patients with bronchial
asthma who visited medical institutions in Niigata
Prefecture; the attending physicians of these patients
are included in the survey. On the basis of these sur-
veys, we have reported the clinical characteristics of
adult bronchial asthma patients,19 bronchial asthma
in the elderly,20 near-fatal asthma,21 perimenstrual
asthma,22 the effect of obesity,23 factors that exacer-
bate asthma,24 the selection of ICS,25 the relationship
between smoking and gender in asthmatics,26 and
changes in asthma management.27,28
The Patient Health Questionnaire-9 (PHQ-9) con-
sisted of nine questions related to depression alone,
and the sensitivity and specificity were reported to be
high compared with other questionnaires for depres-
sion.29 The PHQ-9 differs from other questionnaires
in that it contains no questions associated with anxi-
ety, resulting in a lower likelihood of overestimation
of the depression. Therefore, the PHQ-9 was devel-
oped for the evaluation of the depressive state in ac-
tual clinical care. Recently, the PHQ-9 was found to
be a useful tool for both the evaluation of anti-
depressive medicines30,31 and depressive state in vari-
ous common disease and pathologic conditions.32-37
In 2007, the validity of the Japanese version of the
PHQ-9 (J-PHQ-9) was confirmed by Muramatsu et
al..38 In addition, the Asthma Control Test (ACT) has
been disseminated as an excellent tool for the assess-
ment of asthma control.39,40 Although the ACT was
based on subjective measures of asthma control,41,42
it was reported that the ACT score was strongly asso-
ciated with objective indicators of asthma control
such as lung function.40 In 2008, the ACT was added
to our every two years questionnaire survey. We then
attempted to evaluate the association between de-
pression and control and severity of asthma in Japa-
nese asthmatic patients, using our survey data and
the J-PHQ-9 data.
METHODS
Participation in this study was open to all medical in-
stitutions in Niigata Prefecture if they intended to join
the Niigata Asthma Treatment Study Group. This
study was performed with the approval of the Ethics
Committee at the School of Medicine of Niigata Uni-
versity in Niigata Prefecture, Japan, or at the relevant
participating institution, in accordance with the Ethi-
cal Principles for Medical Research Involving Human
Subjects (Declaration of Helsinki). The study in-
volved 28 large hospitals (200 beds or more), 14
small hospitals (less than 200 beds), and 62 clinics
(no beds). A total of 5260 questionnaires were pre-
pared, and 3146 responses were received (response
rate: 59.8%). The contents of the questionnaire were
written in Japanese. The questionnaire study was per-
formed over two months from September to October
2008. Subjects were adult patients (aged 16 years and
more) with bronchial asthma who regularly visited
the participating institutions for asthma management
(typically once or twice per month). The recruited pa-
tients were asked to complete the questionnaire by
themselves. Individual patients were thus expected to
understand technical terms such as “attack” in the
questionnaire. In addition to this questionnaire, the
ACT and the J-PHQ-9 were separately carried out at
the same time.
Apart from the ACT and the J-PHQ-9, in order to
evaluate their asthma control, patients were asked
about their peak flow meter (PEFM) use, smoking
status, and the incidence of asthma attacks during
the two weeks prior to answering the questionnaire.
The questionnaire included questions on asthma-
related symptoms in the two weeks prior to answer-
ing the questionnaire, including those regarding
cough and sputum in the morning and at night, and
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Table　1　Background and characteristics of study participants
cases 2289
age (years) 55.1 +/- 17.6
gender (male/female/unknown, %) 43.4/55.4/1.2
disease duration (years) 14.2 +/- 13.6
rate of PEFM Use (%) 26.3
smoking status
non-smoker (%) 51.6
ex-smoker (%) 29.5
current smoker (%) 16.4
unknown (%) 2.5
disease type (atopic/non-atopic, unknown %) 68.2/26.1/5.7
ACT score (median [IQR]) 23 [20-25]
attack rate during the last 2 weeks PQ (%) 22.4
morning symptom rate during the last 2 weeks PQ (%) 42.2
nocturnal symptom rate during the last 2 weeks PQ (%) 29.7
sleep disturbance rate during the last 2 weeks PQ (%) 13.1
disease severity (step 1, 2, 3, 4 and unknown [%]) 24.6, 29.3, 26.0, 4.9, 15.2
persistent symptoms during the past year PQ (%) 9.0
work absenteeism rate during the past year PQ (%) 9.9
ICS use rate (%) 86.2
OCS use rate (%) 4.8
LABA use rate (%) 38.0
LTRA use rate (%) 42.4
OSRT use rate (%) 42.9
J-PHQ-9 score (median [IQR]) 1 [0-4]
PEFM, peak-fl ow meter; ACT, Asthma Control Test; IQR, interquartile range; PQ, prior to the questionnaire; ICS, inhaled corticosteroids; 
LABA, long-acting beta agonist; LTRA, leukotriene receptor antagonist; OSRT, oral sustain-released theophylline; J-PHQ-9, the Japanese 
version of patient health questionnaire-9.
sleep disturbances. To evaluate the patients’ condi-
tion in the year prior to answering the questionnaire,
they were also asked to provide information about
their asthma by selecting one of the following three
answers: “few attacks,” “seasonal attacks,” and “fre-
quent attacks.” Furthermore, they were asked about
asthma-related absences from work or school. To
evaluate problems with asthma management and
treatment related to normal activity levels, the ques-
tionnaire also asked patients about their satisfaction
with daily life. The subjects answered by choosing
one of five answers: “very satisfied,” “fairly satisfied,”
“mediocre,” “slightly dissatisfied,” and “dissatisfied.”
In addition to monitoring the completion of the
questionnaire by the patients, physicians were asked
to supply details on current treatment, medication
used for primary control, the type of asthma (atopic
or non-atopic) in accordance with the elevation in se-
rum total IgE or detection of a specific IgE for aller-
gens, and the severity of asthma in accordance with
Asthma Prevention and Management Guideline 2006
(in Japanese) published by Japanese Society of Aller-
gology (JSA). The definition of the severity of asthma
was essentially the same as that used by the Global
Initiative for Asthma.
We measured depressive symptoms using the
nine-item questionnaire of J-PHQ-9. The PHQ-9 is the
9-item depression module from the full PHQ (Patient
Health Questionnaire).43 The PHQ-9 has been devel-
oped from the original PRIME-MD PQ (Patient Ques-
tionnaire).43,44 In the PRIME-MD PQ, the response
categories were dichotomous (‘yes’ or ‘no’).43 As the
first evaluation, we assessed the J-PHQ-9 scores ac-
cording to the original PRIME-ME Patient Health
Questionnaire (PQ) and divided the scores into the
following two groups: ‘J-PHQ-9 score = 0 point group’
is the symptom-screen negative group (SN group). ‘J-
PHQ-9 score 1 point’ is the symptom-screen posi-
tive group (SP group). In the second evaluation, we
used the J-PHQ-9. In contrast to other depression
questionnaires, the PHQ-9 is a dual-purpose instru-
ment that has both the diagnostic measure and the
measure of depression severity. The PHQ-9 can
evaluate the nine Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition (DSM-IV) criteria
for major depressive disorder (MDD). The diagnosis
of MDD can be made by a categorical algorithm us-
ing these nine items. MDD should be considered in
patients who endorse 5 of 9 symptoms as present
“more than half the days” (the 9th item counts if en-
Hasegawa T et al.
478 Allergology International Vol 61, No3, 2012 www.jsaweb.jp
Fig.　1　Number of cases for each Japanese version of patient health questionnaire (J-PHQ-9) score. There 
were no cases with J-PHQ-9 scores of 22 and 26. The number of cases with a J-PHQ-9 score of 0 was 981 (ex-
cluded from this Figure).
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dorsed “several days”) in past 2 weeks, 1 of the first
two symptoms (depressed mood or loss of interest) is
endorsed. Other depressive disorder (ODD) is diag-
nosed if 2, 3, or 4 depressive symptoms have been
present at least “more than half the days in past 2
weeks. As a severity measure, the PHQ-9 can be as-
sessed by calculating a summary score. Though, we
assessed the categorical algorithm diagnosis of major
depressive disorder (MDD), other depressive disor-
der (ODD) using J-PHQ-9 at the first stage. We di-
vided patients into the following groups: ‘the MDD
cases or ODD cases’ are the MDDODD group, ‘non-
MDD cases and non- ODD cases’ are the non-MDD
ODD group. Next, we also measured the severity of
depressive states according to the total score of J-
PHQ-9 at the second stage, the score is ranging from
0 to 27, and the points of 0-4, 5-9, 10-14, 15-19, 20-27
respectively represent minimal, mild, moderate,
moderate-severe, and severe state of depressive
symptoms. The clinical description of each depres-
sive state is as follows45,46:
1) Minimal depressive state; An individual with
minimal depressive state is distressed from one de-
pressive symptom to four symptoms very occasion-
ally and has slight difficulty in continuing with ordi-
nary work and social activities. The recommended
treatment for minimal depressive state is reassurance
or supportive counseling. 2) Mild depressive state;
An individual with mild depressive state is usually dis-
tressed from one depressive symptom to four symp-
toms and has some difficulty in continuing ordinary
work and social activities, but will probably not cease
to function completely. The recommended treatment
for mild depressive state is reassurance or supportive
counseling by general physician or medical staff. If
the symptoms get worse, the patient is recommended
to consult a mental professional physician (psychoso-
matic medicine) or psychiatrist. 3) Moderate depres-
sive state; An individual with moderate depressive
state is usually distressed from two depressive symp-
toms to four symptoms and usually has considerable
difficulty in continuing social, work or domestic ac-
tivities. The recommended treatment for moderate
depressive state is watchful waiting and supportive
counseling by a mental professional physician (psy-
chosomatic medicine) or psychiatrist. If there is no
improvement after one or more months, the physi-
cian may consider use of an antidepressant and brief
psychological counseling (CBT: cognitive behavior
therapy). 4) Moderately severe and severe depres-
sive state; An individual with moderately severe and
severe depressive symptoms has considerable dis-
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Table　2　Numbers and rates for each group
J-PHQ-9 Score (median [IQR]) case number (%)
SN group 0 [0-0] 981 (42.9)
SP group 3 [2-6] 1308 (57.1)
minimal DS subgroup 2 [1-3] 868 (37.9)
mild DS subgroup 6 [5-8] 289 (12.6)
more than mild DS subgroup 13 [11-16] 151 (6.6)
moderate DS group 11 [11-11.3] 92 (4.0)
moderate-severe DS group 16.5 [16-18] 44 (1.9)
severe DS group 23 [20-24] 15 (0.7)
J-PHQ-9, the Japanese version of patient health questionnaire-9; IQR, interquartile range; SN group, symptom-screen negative group; 
SP group, symptom-screen positive group; DS, depressive state.
Table　3　Comparison of age, gender and disease duration in each group
age (mean +/- SD, years) gender (male/female [%]) disease duration (mean +/- SD, years)
SN group 58.8 +/- 16.4 482/486 (49.1/49.5) 14.1 +/- 13.5
SP group 52.3 +/- 16.4*** 512/781 (39.1/59.7)*** 14.3 +/- 13.7
minimal DS subgroup 52.8 +/- 17.6 351/506 (40.4/58.3) 14.3 +/- 13.7
mild DS subgroup 51.8 +/- 18.6 111/174 (38.4/60.2) 14.0 +/- 13.1
more than mild DS subgroup 50.6 +/- 19.7 50/101 (33.1/66.9) 15.2 +/- 15.0
moderate DS group 50.5 +/- 20.7 30/62 (32.6/67.4) 14.8 +/- 13.8
moderate-severe DS group 50.8 +/- 18.2 15/29 (34.1/65.9) 18.4 +/- 17.4
severe DS group 50.6 +/- 20.2 5/10 (33.3/66.7) 7.3 +/- 11.2¢
SN group, symptom-screen negative group; SP group, symptom-screen positive group; DS, depressive state.
***P < 0.001 v.s. SN DS group, ¢P < 0.05 v.s. moderate-severe DS group.
Table　4　Comparison of  disease type, peak fl ow meter use and smoking status in each group
disease type 
(atopic/non-atopic [%])
PEFM use rate 
(%)
smoking status
 (non-smoker/ex-smoker/current smoker [%])
SN group 64.3/29.2 27.4 50.4/30.7/15.9
SP group 71.0/23.9** 26.2 52.5/28.7/16.8
minimal DS subgroup 72.4/22.1 26.7 53.5/28.9/15.8
mild DS subgroup 67.1/27.5 24.9 48.4/30.1/19.0
more than mild DS subgroup 70.9/27.2 25.8 55.0/24.5/18.5
moderate DS group 71.8/25.0 27.2 63.0/21.7/15.2
moderate-severe DS group 65.9/34.1 20.5 45.5/27.3/20.5
severe DS group 80.0/20.0 33.3 33.3/33.3/33.3
PEFM, peak fl ow meter; SN group, symptom-screen negative group; SP group, symptom-screen positive group; DS, depressive state. 
**P < 0.01 v.s. SN group.
tress and has a marked feature such as agitation, loss
of self-esteem or feelings of uselessness or guilt and
risk of suicide. The sufferer usually has severe diffi-
culty in continuing with social, work, or domestic ac-
tivities. The recommended treatment for moderately
severe and severe depressive states is antidepres-
sants alone or in combination with psychological
counseling (CBT) by psychiatrist. Comparisons were
performed between the SN and SP groups and be-
tween the MDDODD and non-MDDODD groups,
among the minimal, mild and more than mild (MTM)
depressive state subgroups that included moderate,
moderate-severe and severe depressive state group,
and among the moderate, moderate-severe and se-
vere depressive state groups.
Representative results for continuous variables
Hasegawa T et al.
480 Allergology International Vol 61, No3, 2012 www.jsaweb.jp
Fig.　2　The ACT score in the symptoms-screen negative 
(SN) and symptoms-screen positive (SP) groups. The trans-
verse short line expressed the median of the ACT score and 
the vertical line indicates the interquartile range of the ACT 
score. The ACT score in the SP group was signifi cantly low-
er (***p < 0.001) than that in SN group.
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Fig.　3　The ACT score in the minimal ‘depressive case’ 
subgroup, mild subgroup and MTM DS subgroup. The trans-
verse short line expresses the median of the ACT score and 
the vertical line indicates the interquartile range of the ACT 
score. There was a signifi cant variation of the ACT score 
among the minimal, mild MTM DS subgroups. The ACT 
score in the mild and more than mild subgroups was signifi -
cantly lower (###p < 0.001) than that in the minimal DS sub-
group. The ACT score in the MTM DS subgroup was signifi -
cantly lower ($$p < 0.01) than that in the mild DS subgroup. 
MTM, more than mild; DS, depressive state.
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were expressed as arithmetic means and standard de-
viations. Intergroup differences in terms of continu-
ous variables were evaluated using the Kruskal-
Wallis test and Wilcoxon’s rank sum test with the
Bonferroni correction. A Chi-square test with the
Bonferroni correction was also used to assess the sig-
nificance of differences in proportions among groups.
All statistical analyses were performed with the statis-
tical software StatView 5.0 PowerPC version (SAS In-
stitute Inc., Cary, NC, USA). For all statistical analy-
ses, a P-value < 0.05 was considered to be significant.
RESULTS
PATIENT CHARACTERISTICS
Patient characteristics are summarized in Table 1. Of
the asthmatic patients who answered the question-
naire, 2289 subjects who completed the J-PHQ-9 and
ACT were analyzed in this study. The age (mean ±
SD), gender (malefemale [%]), disease duration
(mean ± SD), disease type (atopicnon-atopic [%])
and the rate of peak-flow meter use were 55.1 ± 17.6
years, 43.4％55.4%, 14.2 ± 13.6 years, 68.2％26.1%
and 26.3%, respectively. Rates of non-smokers, ex-
smokers and current smokers were 51.6%, 29.5% and
16.4%, respectively. The ACT and J-PHQ-9 scores
(median [interquartile range (IQR)]) were 23 [20-25]
and 1 [0-4], respectively. The attack rate during the
two weeks prior to answering the questionnaire was
22.4%, and rates of morning symptoms, nocturnal
symptoms and sleep disturbance were 42.2%, 29.7%
and 13.1%, respectively. The rates of persistent symp-
toms and absenteeism from work during the year
prior to answering the questionnaire were 9.0% and
9.9%, respectively. While the rate of use of inhaled
corticosteroids (ICS) was over 80%, rates for use of
long-acting beta agonists (LABAs), leukotriene recep-
tor antagonists (LTRAs) and oral sustained-released
theophylline (OSRT) were around 40%. On the other
hand, oral corticosteroids (OCS) were used in under
5%.
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Fig.　4　The ACT score in the moderate ‘depressive case’ 
group, moderate-severe group and severe DS groups. The 
transverse short line expresses the median of the ACT score 
and the vertical line indicates the interquartile range of the 
ACT score. There was no signifi cant variation of the ACT 
score among the moderate, moderate-severe and severe DS 
groups. DS, depressive state.
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NUMBERS AND RATES FOR EACH GROUP
A visual representation of the distribution of J-PHQ-9
scores in these patients with asthma is shown in Fig-
ure 1, which shows the numbers for each J-PHQ-9
score except the score of zero; the numbers and the
rates for each group, including the SN and SP group,
are summarized in Table 2. There were 981 (42.9%)
and 1314 (57.1%) cases in the SN and SP groups, re-
spectively. The respective numbers (rates) in mini-
mal, mild, moderate, moderate-severe and severe de-
pressive state groups were 868 (37.9%), 289 (12.6%),
92 (4.0%), 44 (1.9%) and 15 (0.7%), respectively. The
numbers (rate) for the MTM subgroup were 152
(6.6%). There were 74 MDD (3.2%) and 57 ODD
cases (2.5%) in the MDDODD group, although
these were not described in Table 2.
COMPARISON OF PATIENT DEMOGRAPHICS IN
EACH GROUP
Tables 3 and 4 summarize our results. Patients in the
SP group were significantly younger and more were
female than in the SN group, but there was no signifi-
cant difference in the duration of illness between the
groups. There were no significant differences in age,
gender and disease duration among the minimal,
mild and MTM depressive state subgroups. Within
the moderate, moderate-severe and severe depres-
sive state groups, those in the severe depressive state
group were significantly younger than those in the
moderate-severe depressive state group, without any
other significant differences. On examination of dis-
ease type, rate of use of PEFM and smoking status,
the only difference between groups was related to
disease type (Table 4). There was a significantly
higher rate of atopic type in the SP group than in the
SN group. There were no significant differences in
age, gender, disease duration, disease type, rate of
use of PEFM and smoking status between the MDD
ODD and non-MDDODD groups.
COMPARISON OF THE ACT SCORE
Figure 2 shows ACT scores in the SN and SP groups.
The ACT score in the SP group was significantly
lower than that in the SN group. Figure 3 shows ACT
scores in the minimal, mild and MTM depressive
state subgroups. There was a significant variation in
the ACT score among the minimal, mild and MTM
depressive state subgroups. The ACT score in the
mild and MTM depressive state subgroups was sig-
nificantly lower than that in the minimal depressive
state subgroup. The ACT score in the MTM depres-
sive state subgroup was also significantly lower than
that in the mild depressive state subgroup. There was
no significant variation in the ACT score among the
moderate, moderate-severe and severe depressive
state groups (Fig. 4). The ACT score in the MDD
ODD group (21 [15-24]) was significantly lower than
that in the non-MDDODD group (23 [20-25]).
COMPARISON OF ATTACK RATES, MORNING
SYMPTOM RATES, NOCTURNAL SYMPTOM
RATES AND SLEEP DISTURBANCE RATES
DURING THE TWO WEEKS PRIOR TO ANSWER-
ING THE QUESTIONNAIRE
These data are summarized in Table 5. The attack
rate, morning symptom rate, nocturnal symptom rate
and sleep disturbance rate during the two weeks
prior to answering the questionnaire were signifi-
cantly higher in the SP group than in the SN group.
Among the minimal, mild and MTM depressive state
subgroups, although there was no significant vari-
ation in attack rates, there was significant variation in
the morning symptom rates, nocturnal symptom
rates and sleep disturbance rates. The sleep distur-
bance rate in the mild depressive state subgroup and
the rates of morning symptoms, nocturnal symptoms
and sleep disturbance in the MTM depressive state
subgroup were significantly higher than those in the
minimal depressive state subgroup. There were no
significant variations in the attack rate, morning
symptom rate, nocturnal symptom rate and sleep
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Table　5　Comparison of attack rates, morning symptom rates, nocturnal symptom rates and sleep disturbance rates during the 
2 weeks prior to the questionnaire, in each group
AR during 2W (%) MSR during 2W (%) NSR during 2W (%) SDR during 2W (%)
SN group 14.6 29.6 16.4 3.7
SP group 28.3*** 51.8*** 39.7*** 20.2***
minimal DS subgroup 26.6 48.4 36.4 16.2
mild DS subgroup 31.1 54.7 43.6 24.6＃＃
more than mild DS subgroup 31.8 65.6＃＃ 51.0＃＃ 34.4＃＃＃
moderate DS group 27.2 62.0 46.7 27.2
moderate-severe DS group 40.9 75.0 61.4 40.9
severe DS group 33.3 60.0 46.7 60.0
AR, attack rate; 2W, the 2 weeks prior to the questionnaire; MSR, morning symptom rate; NSR, nocturnal symptom rate; SDR, sleep dis-
turbance rate; SN group, symptom-screen negative group; SP group, symptom-screen positive group; DS, depressive state.
***P < 0.001 v.s. SN group, ＃＃＃P < 0.001, ＃＃P < 0.01 v.s. minimal DS subgroup.
Table　6　Comparison of rates of persistent symptoms and work absenteeism during the year prior to the questionnaire, and 
satisfaction with daily life, in each group
PS during 1Y (%) WAR during 1Y (%) satisfaction with daily life (VS + S/M + SU + U [%])
SN group 5.2 3.9 89.7/9.4
SP group 11.9*** 12.6*** 70.0/29.8***
minimal DS subgroup 9.1 9.6 81.8/18.1
mild DS subgroup 16.3＃＃ 17.3＃＃ 52.2/47.8＃＃＃
more than mild DS subgroup 19.9＃＃＃ 21.2＃＃＃ 36.4/62.9＃＃＃ , $$
moderate DS group 14.1 14.1 41.3/57.6
moderate-severe DS group 34.1¥ 31.8¥ 27.3/72.7
severe DS group 13.3 33.3 33.3/66.7
PS, persistent symptoms; 1Y, the year prior to the questionnaire; WAR, work absenteeism rate; VS + S, very satisfi ed and satisfi ed; M + 
SU + U, mediocre, slightly dissatisfi ed and not satisfi ed; SN group, symptom-screen negative group; SP group, symptom-screen positive
group; DS, depressive state.
***P < 0.001 v.s. SN group, ＃＃＃P < 0.001, ＃＃P < 0.01 v.s. minimal DS subgroup, $$P < 0.01 v.s. mild DS subgroup, ¥P < 0.05 v.s. moder-
ate DS group.
disturbance rate during the two weeks prior to an-
swering the questionnaire among the moderate,
moderate-severe and severe depressive state groups.
Morning symptom rate (57.3% vs. 41.3%), nocturnal
symptom rate (42.7% vs. 28.9%) and sleep disturbance
rate (32.1% vs. 12.0%) during the two weeks prior to
answering the questionnaire in the MDDODD
group were also higher than those in the non-MDD
ODD group, although there was no significant differ-
ence of attack rate (MDDODD vs. non-MDDODD
group).
COMPARISON OF RATES OF PERSISTENT
SYMPTOMS AND ABSENTEEISM FROM WORK
DURING THE YEAR PRIOR TO ANSWERING THE
QUESTIONNAIRE, AND SATISFACTION WITH
DAILY LIFE
These findings are summarized in Table 6. The rates
of persistent symptoms and absenteeism during the
year prior to answering the questionnaire were sig-
nificantly higher in the SP group than in the SN
group. Among the minimal, mild and MTM depres-
sive state subgroups, there was significant variation
in the rates of persistent symptoms and absenteeism,
and these metrics were significantly greater in the
mild and MTM depressive state subgroups than
in the minimal depressive state subgroup. There
was significant variation in the rates of persistent
symptoms and absenteeism among the moderate,
moderate-severe and depressive state severe groups,
and these parameters were greater in the moderate-
severe depressive state group than in the moderate
depressive state group. The rates of persistent symp-
toms (16.8% vs. 8.6%) and absenteeism (19.1% vs.
8.2%) during the year prior to answering the question-
naire were significantly higher in MDDODD group
than in the non-MDDODD group. As regards satis-
faction with daily life, responses were classified into
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Fig.　5　The open and closed square bars represent the rate of each step 
in disease severity, as defi ned by the Japanese Society of Allergology 
(JSA), in the symptoms-screen negative (SN) and symptoms-screen posi-
tive (SP) groups, respectively. The rate of step 1 in the SP group was sig-
nifi cantly lower than that in the SN group. The rates for steps 3 and 4 in the 
SP group were signifi cantly higher than those in the SN group. There was 
no signifi cant difference in the rate of step 2 between the SN and SP 
groups. **p < 0.01, ***p < 0.001 v.s. SN group. NS, not signifi cant.
step1 step2 step3 step4
30
20
10
0
SN group
SP group
Severity
(%)
**
***
***
NS
two, those who answered “very satisfied and satis-
fied” and those who responded with “mediocre,
slightly unsatisfied or unsatisfied”, and then analyzed.
The rate of the later was significantly greater in the
SP group than in the SN group. There was significant
variation in the rate of a “very satisfied and satisfied”
response among the minimal, mild and MTM depres-
sive state subgroups, and the response rate for this
choice was significantly lower in the mild and STM
depressive state subgroups than that in the minimal
depressive state subgroup. The rate of “very satisfied
and satisfied” in the MTM depressive state subgroup
was also significantly lower than that in the mild de-
pressive state subgroup. There was no significant
variation in the rate of “very satisfied and satisfied”
among the moderate, moderate-severe and severe de-
pressive state groups. The rate of the “mediocre,
slightly unsatisfied or unsatisfied” (63.4% vs.18.5%)
was significantly greater in the MDDODD group
than in the non-MDDODD group.
COMPARISON OF DISEASE SEVERITY
Comparisons of disease severity are summarized in
Figure 5-7. Step 1 severity was significantly less fre-
quent in the SP group than in the SN group, and step
3 and 4 rates were more common in the SP group
(Fig. 5). Although there were no significant variations
among the minimal, mild and MTM depressive state
subgroups, there was significant variation in disease
severity among these groups, and the step 4 rate in
the MTM depressive state subgroup was significantly
higher than that in the minimal depressive state sub-
group (Fig. 6). There was no significant variation in
disease severity among the moderate, moderate-
severe and severe depressive state groups (Fig. 7).
The J-PHQ-9 scores (median [IQR]) in each group of
Step 1, 2, 3 and 4 was 1 [0-3], 1 [0-3], 2 [0-4] and 2.5
[0-7.25], respectively. The J-PHQ-9 scores in the
groups of Step 3 and 4 were significantly higher than
those in the groups of Step 1 and 2.
COMPARISON OF MEDICATIONS
A summary of medication is shown in Table 7. Rates
of use of OCS, ICS, LTRA and LABA were signifi-
cantly higher in the SP group than in the SN group,
although there was no significant difference in rates
of use of OSRT between the SP and SN groups.
There were no significant variations in rates of use of
OCS, ICS, LABA, LTRA and OSRT among the mini-
mal, mild and MTM depressive state subgroups and
among the moderate, moderate-severe and severe DS
groups. Rate of use of OCS in the MDDODD group
(10.7% vs. 4.4%) was significantly higher than that in
the non-MDDODD group.
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Fig.　6　The open, dotted and solid bars represent the rate of each step in disease sever-
ity, as defi ned by the Japanese Society of Allergology (JSA), in the minimal, mild and 
MTM DS subgroups, respectively. There were no signifi cant variations in the rates of 
steps 1, 2 and 3 among the minimal, mild and MTMDS subgroups. There was a signifi -
cant variation in the rate of step 4 among the minimal, mild and MTM DS subgroups, and 
the rate of step 4 in the DS MTM subgroup was signifi cantly higher than that in the mini-
mal DS subgroup. ##p < 0.01 v.s. minimal DS subgroup. NS, not signifi cant; DS, depres-
sive state; MTM, more than mild.
Minimal DS subgroup 
Mild DS subgroup
MTM DS subgroup
step1 step2 step3 step4
30
20
10
0
Severity
(%) NS
NS
NS
##
Fig.　7　The open, dotted and fi lled bars represent the rate of each step in disease severity, as 
defi ned by the Japanese Society of Allergology (JSA), in the moderate, moderate-severe and se-
vere DS groups, respectively. There were no signifi cant variations in the rates of steps 1, 2 , 3 and 
4 among the moderate, moderate-severe and severe DS groups. NS, not signifi cant; DS, depres-
sive state.
moderate DS group
moderate-severe DS group
severe DS group
step1 step2 step3 step4
Severity
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Analysis of Depression Using J-PHQ-9
Allergology International Vol 61, No3, 2012 www.jsaweb.jp 485
Table　7　Comparison of medication in each group
OCS use rate 
(%)
ICS use rate 
(%)
LABA use rate 
(%)
LTRA use rate 
(%)
OSRT use rate 
(%)
SN group 3.3 83.4 31.3 38.5 42.5
SP group 5.9** 88.2*** 43.0*** 45.3** 43.3
minimal DS subgroup 5.1 88.9 42.1 44.0 41.0
mild DS subgroup 6.2 87.5 45.0 47.8 48.1
more than mild DS subgroup 9.9 85.4 44.4 47.7 47.0
moderate DS group 9.8 82.6 44.6 48.9 44.6
moderate-severe DS group 13.6 93.2 47.7 43.2 52.3
severe DS group 0.0 80.0 33.3 50.0 46.7
OCS, oral corticosteroid; ICS, inhaled corticosteroid; LABA, long acting beta agonist; LTRA, leukotriene receptor antagonist; OSRT, oral 
sustained-released theophylline; SN group, symptom-screen negative group; SP group, symptom-screen positive group; DS, depressive
state. 
***P < 0.001, **P < 0.01 v.s. SN group.
DISCUSSION
The aim of this study was to investigate the associa-
tion between asthma control and severity, and de-
pression, using a questionnaire survey containing the
ACT and the PHQ-9. A remarkable finding was that
just 42.9% of patients with asthma had no evidence of
a depressive state, although other studies show an
odds ratio of 1.6 for depression in those with asthma,
compared to those without asthma.11-13 Although the
PHQ-9 was reported to be an excellent tool for the
evaluation of depression in various common diseases
and conditions32-37 in actual clinical care, there have
been few studies of depression in asthmatic patients
using the PHQ-9. This study appears to be the first
report of analyses of depression in patients with
asthma using the PHQ-9. We cannot therefore com-
pare our findings with those from other studies of de-
pression in asthma using the PHQ-9.
In studies of depression that used the PHQ-9 in pa-
tients with heart failure, rates of PHQ-9 scores over
11 and scores between 9 and 11 were 24% and 15%, re-
spectively.47 In our study, the former rate was 4.5%
and the latter was 4.8% (data not shown). In patients
with acute myocardial infarction, a PHQ-9 score of
more than 9 was present in 29%,33 while the rate was
just 8.1% in this study. With head and neck cancer,
the mean value of the J-PHQ-9 score in patients with
stage 4 disease was approximately twice that in pa-
tients at step 4 in our study.48 Compared with these
pathologic conditions of heart disease and cancer, de-
pression might play a lesser role in asthma. However,
with step 4 severity, the J-PHQ-9 score was over 9 in
18.8% (data not shown), indicating that more atten-
tion should be paid to depression in patients with se-
vere asthma.
The most reliable indicator of asthma control in
this study was the ACT score. It was very clear that
asthma in those with depression was less well con-
trolled than in those without depression (Fig. 2 and
the comparison of the ACT score between the MDD
ODD and non-MDDODD group), and asthma con-
trol was worse with increasing levels of depressive
state (Fig. 3). Other indicators of asthma control, in-
cluding asthma attacks and symptoms during the two
weeks prior to answering the questionnaire (Table 5),
and asthma-related conditions during the year prior
to answering the questionnaire (Table 6), supported
the findings revealed by the ACT score. Note that not
only subjective indicators of asthma control such as
patients’ asthma symptoms but also the ACT score,
accepted as being strongly associated with objective
indicators of asthma control,40 showed a negative as-
sociation between asthma control and severity of de-
pression. Among the moderate, moderate-severe and
severe depressive state groups, however, there was
no consistent association between asthma control and
severity of depression. Although there may have
been too few cases in the analysis to detect a differ-
ence among these subgroups, it was difficult to ex-
plain why absolute values of several indicators of con-
trol, such as the ACT score in the moderate-severe
depressive state group, did not follow the trend.
These findings suggest that the relationship between
asthma control and severity of depressive state might
be influenced by two characteristics, and that inde-
pendent factors that affect asthma control might play
an important role in advanced depression associated
with asthma. Further study will be required to clarify
these issues.
There were also associations between asthma se-
verity and the severity of depressive state, just as
there were between asthma control and severity of
depressive state (Fig. 5-7). Because asthma severity
was influenced not only by asthma control but also
the medication required to achieve asthma control,
there were fewer differences between asthma sever-
ity and severity of depressive state than there were
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between asthma control and severity of depressive
state, among the minimal, mild and MTM depressive
state subgroups. This finding suggests that the differ-
ences in medication (Table 7) might be related to the
association between disease severity and severity of
depressive state. The reason why there were no sig-
nificant variations in the rates of steps 1, 2, 3 and 4
among the moderate, moderate-severe and severe de-
pressive state groups (Fig. 7) might be same as that
why the ACT score in the moderate-severe depres-
sive state group did not follow the trend as mentioned
above. As satisfaction with daily life was thought to
reflect basic asthma control, it is credible that the
proportion of those who felt “very satisfied or satis-
fied” decreased as the degree of depression became
more severe. Satisfaction with daily life might influ-
ence and be influenced by asthma severity.
In this study, there were three differences in pa-
tients’ characteristics in the SP and SN groups, that is
their age, gender and disease type. When patients
were divided into two groups by gender or disease
type, there was no significant difference in ACT
score, indicating that gender and disease type might
influence the depressive state, independent of asthma
control. When divided into two groups by age (<64:
‘young’ group,64: ‘elderly’ group), there was a small
but significant difference in ACT score, and the mean
ACT score in the younger group was 0.6 below that in
the elderly group (data not shown), while the differ-
ence in the ACT mean score between the SP and SN
groups was 2.1, suggesting that the age has only a
minor effect on the asthma control through its effects
on the severity of depressive state.
In summary, we tried to determine the association
between asthma control and severity, and depressive
state using a questionnaire that included the ACT and
PHQ-9 questionnaires. This study is the first large-
scale investigation of the use of the PHQ-9 in patients
with asthma. There was a clear association between
asthma control, mainly evaluated with the use of the
ACT score, and asthma severity (based on JSA crite-
ria) on the one hand, and the presence of a depres-
sive state, evaluated using the J-PHQ-9, on the other.
With progression from moderate to severe depres-
sion based on the J-PHQ-9 score, the existence of
other depression-associated factors unrelated to
asthma control and severity might be assumed. Fur-
ther investigation of this hypothesis will be required.
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